Skip to main content
. 2020 Feb 1;13(2):286–294.

Figure 2.

Figure 2

LVEF, cTnl, and NT-proBNP levels between cardiotoxicity and non-cardiotoxicity patients. LVEF was lower in patients with cardiotoxicity compared to patients with non-cardiotoxicity at each visit (A); cTnI was higher in patients with cardiotoxicity compared to patients with non-cardiotoxicity at each visit (B); NT-proBNP was higher at baseline (M0), but similar in patients with cardiotoxicity compared to patients with non-cardiotoxicity at each following visit (C). Comparison of LVEF, cTnl, and NT-proBNP levels between cardiotoxicity patients and non-cardiotoxicity patients at each visit was determined by Wilcoxon rank test. P<0.05 was considered significant. LVEF, left ventricular ejection fraction; cTnI, cardiac troponin I; NT-proBNP, N terminal pro B type natriuretic peptide.